4th Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$1,460,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

10 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

AMP Cap Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Drug Pricing Drug wastage rebates policy issues Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicaid rebates and waiver policy issues Medicare Part A, B and D Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues Inflation penalties policy issues Medicare negotiations policy issues VA drug pricing issues HR 5376 Build Back Better Act drug reimbursement policies HR 3

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Centers For Medicare and Medicaid Services (CMS); White House Office; Office of Management & Budget (OMB); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); SENATE; U.S. Agency for International Development (USAID); Energy, Dept of; State, Dept of (DOS); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: H.R. 3 (117th), H.R. 5376 (117th)

Energy/Nuclear ENG

Increasing domestic supply of Actinium 225

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —

Contacted: White House Office; State, Dept of (DOS); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); SENATE; Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Energy, Dept of; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Veterans VET

Health care collaboration opportunities

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); White House Office; Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Energy, Dept of; SENATE; State, Dept of (DOS)

Science/Technology SCI

Artificial intelligence Data and digital technologies

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
SHELLY MUI-LIPNIK —
COURTNEY PIRON —

Contacted: Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Energy, Dept of; Food & Drug Administration (FDA); White House Office; Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); Veterans Affairs, Dept of (VA); Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); State, Dept of (DOS)

Trade (domestic/foreign) TRD

Access to Medicines Issues Biopharmaceutical Innovation Policies China Agreement Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Quality of Medicines Regulatory Cooperation Supply chain and China Task Force policy issues Tariffs Trade Policy USTR Special 301 Report/National Trade Estimate WTO IP Waiver Export Controls

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); White House Office; State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES; Energy, Dept of

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Administration's FY 2022 Revenue Proposals Base Erosion Anti-Abuse Tax (BEAT) OECD Digital Tax Orphan Drug Tax Pharmaceutical supply chain incentives R&D Amortization Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n) & 163(o)) Stopping Harmful Inversions and Ending Low-Tax Developments (SHIELD) Tax Treaties Thin Capitalization Rules 163(j) U.S. Corporate Tax Build Back Better Act Tax Provisions

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: White House Office; Health & Human Services, Dept of (HHS); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); U.S. Trade Representative (USTR); Office of Management & Budget (OMB); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Energy, Dept of; Commerce, Dept of (DOC); U.S. Agency for International Development (USAID)

Copyright/Patent/Trademark CPT

Antitrust Legislation Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars BPCIA Compulsory licenses Data Exclusivity Intellectual Property Issues in Reponse to coronavirus Inter Partes Review at PTO Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Patents S.1435, Affordable Prescriptions for Patients Act of 2021 S.225, Competition and Antitrust Law Enforcement Reform Act Section 101 H.R. 2883, the Stop Stalling Access to Affordable Medications H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act HR 1629/S. 250 - Fairness in Orphan Drug Exclusivity Act

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Food & Drug Administration (FDA); State, Dept of (DOS); Office of Management & Budget (OMB); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); SENATE; Energy, Dept of; Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); U.S. Agency for International Development (USAID); White House Office

Bills named: H.R. 2873 (117th), H.R. 2891 (117th), H.R. 2884 (117th), S. 225 (117th), S. 250 (117th), H.R. 2883 (117th), S. 1435 (117th), H.R. 1629 (117th)

Health Issues HCR

21st Century Cures Act 2.0 340B Drug Discount Program Advanced Research Projects Agency for Health (ARPA-H) AMP Cap Biosimilar approval and reimbursement policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions BLOCKING Act Buy American and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Cell, gene and radioligand therapies Comprehensive Immunosuppressant Drug Coverage for Kidney Transplant Patients Act of 2020 Co-pay accumulator programs COVID-19 Defense Production Act Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and counterfeit policy issues Drug shortages policy issues FDA modernization policy issues Foreign manufacturing policy issues Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement FY 2022 Labor-HHS Appropriations H.R.1319, American Rescue Plan Act of 2021 H.R.133, Consolidated Appropriations Act for FY 2021 H.R.2815, The BIOSIM Act H.R.2855, Star Rating for Biosimilars Act H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.5463, Drug Pricing Transparency and Accountability Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 4811, Medicare Negotiation and Competitive Licensing Act of 2021 Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Medicaid Generics Penalty Fix Medicaid Payment Reform Notice of Benefit Payment Parameters (NBPP) Orphan Drugs Outcomes based contracting/value based arrangements Part B Home Infusion Patient assistance program policy issues PDUFA, BSUFA, GDUFA Pharmaceutical quality Pharmaceutical supply chain H.R.5388/S.2740 PREPARE ACT of 2021 (API stockpiling) Priority Review Voucher (PRV) Regulatory efficiencies policy issues S.1427, HR 2869 - Increasing Access to Biosimilars Act of 2021 S.164, Advancing Education on Biosimilars Act of 2021 Transparency policy issues Vaccines White House National Biodefense Strategy H.R. 5416, The Give Kids a Chance Act Part D Benefit Re-design H.R. 6000: Cures 2.0 Act H.R.19 - Lower Costs, More Cures Act of 2021

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Energy, Dept of; Veterans Affairs, Dept of (VA); White House Office; State, Dept of (DOS); U.S. Agency for International Development (USAID); Commerce, Dept of (DOC)

Bills named: H.R. 5463 (117th), S. 2740 (117th), H.R. 4811 (117th), H.R. 5388 (117th), H.R. 5260 (117th), H.R. 2815 (117th), H.R. 2855 (117th), H.R. 19 (117th), H.R. 5416 (117th), H.R. 1319 (117th), S. 164 (117th), H.R. 3 (117th), H.R. 2869 (117th), H.R. 6000 (117th), S. 1427 (117th), H.R. 133 (117th)

Budget/Appropriations BUD

Advanced Research Projects Agency for Health (ARPA-H) Biosimilars Drug Pricing Fiscal year 2022 Appropriations Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement H.R.1, For the People Act of 2021 H.R.1319, American Rescue Plan Act of 2021 H.R.133, Consolidated Appropriations Act for FY 2021 H.R.5376, Build Back Better Act Importation National Defense Authorization Act FY 2022 Prescription Drug User Fee Act (PDUFA) VII Priorities Value of Medicine

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: White House Office; U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Energy, Dept of; Commerce, Dept of (DOC); State, Dept of (DOS); Veterans Affairs, Dept of (VA)

Bills named: H.R. 1 (117th), H.R. 5376 (117th), H.R. 133 (117th), H.R. 1319 (117th)

Labor Issues/Antitrust/Workplace LBR

Anti-Trust Reform The Competition and Antitrust Law Enforcement Reform Act (S.225):

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Energy, Dept of; White House Office; Veterans Affairs, Dept of (VA); U.S. Trade Representative (USTR); SENATE; State, Dept of (DOS); Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: S. 225 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.